Welcome to our dedicated page for Ovid Therapeutics news (Ticker: OVID), a resource for investors and traders seeking the latest updates and insights on Ovid Therapeutics stock.
Ovid Therapeutics Inc. reports developments as a biopharmaceutical company developing targeted small-molecule medicines for brain disorders and symptoms linked to excess neural excitability. Recurring news centers on its KCC2 direct-activator portfolio, including OV350, OV4071 and next-generation candidates, as well as OV329, a next-generation GABA-aminotransferase inhibitor being developed for treatment-resistant seizures and related rare epileptic disorders.
Company updates also cover clinical and translational data, regulatory clearances for early-stage studies, R&D events, financial results, private-placement and warrant-related capital actions, investor conference participation, and leadership or governance changes tied to the advancement of its CNS pipeline.
Ovid Therapeutics (NASDAQ: OVID) has published findings regarding its compound OV350 in Cell Reports Medicine, highlighting its potential in treating treatment-resistant epilepsies. OV350 directly activates the KCC2 co-transporter, reducing neuronal hyperexcitability and intracellular chloride accumulation. Preclinical studies reveal that OV350 can arrest benzodiazepine-resistant seizures, restore efficacy of benzodiazepines, and reduce neuronal injury following status epilepticus. The compound was found to penetrate the brain effectively without causing sedation. Ovid aims to explore various modes of delivery for OV350 and other KCC2 activators.
Ovid Therapeutics Inc. (NASDAQ: OVID) announced participation in a panel titled “Orphan Epilepsies” at the Cowen 43rd Annual Healthcare Conference on March 6, 2023, at 12:50 p.m. ET in Boston, Massachusetts. A live webcast will be available on their website, with an archived replay following the event.
Ovid specializes in biopharmaceuticals aimed at treating epilepsies and brain disorders. Their development pipeline includes OV329 for treatment-resistant seizures and OV350 targeting the KCC2 transporter. They also hold a financial interest in soticlestat, currently in Phase 3 trials, which is being developed by Takeda.
Ovid Therapeutics Inc. (NASDAQ: OVID) announces the appointment of Manoj Malhotra, M.D., as Chief Medical Officer and Toshiya Nishi, D.V.M., as Head of Epilepsy Research. Dr. Malhotra brings extensive experience in neurological medicine and has held senior roles at major pharmaceutical companies. He aims to enhance Ovid’s research pipeline for seizure treatments. Dr. Nishi, co-inventor of soticlestat, will focus on Ovid’s KCC2 transporter activators. Both leaders are expected to play critical roles in advancing Ovid’s innovative therapies for epilepsy, showcasing the company’s commitment to improving the lives of those affected by brain disorders.
Ovid Therapeutics has initiated a Phase 1 study for OV329, a next-generation GABA-aminotransferase inhibitor, aimed at treating rare epilepsies. This first-in-human trial, conducted at Duke University, will assess the safety and efficacy of OV329 in healthy volunteers. The study's design includes single and multiple ascending doses. With over 60 participants expected, results are anticipated in the first half of 2024. This innovative treatment targets treatment-resistant seizures, potentially offering improved safety and efficacy compared to existing medications.
Ovid Therapeutics announced promising preclinical data for OV329 and OV350 at the 2022 American Epilepsy Society Annual Meeting. OV329, a next-generation GABA-aminotransferase inhibitor, showed potential efficacy and safety with low, chronic dosing, outperforming existing treatments. OV350 demonstrated efficacy in activating KCC2 to combat refractory status epilepticus and reduce neuronal damage. Both programs aim to address treatment-resistant epilepsies, providing hope for patients. Key data from NIH's Epilepsy Therapy Screening Program highlighted significant seizure protection in animal models.
Ovid Therapeutics reported Q3 2022 results showing a net loss of approximately $12 million, equal to $0.17 per share. The company ended the quarter with cash and equivalents of $137.9 million, expected to support operations into 2025. Ovid aims to initiate a Phase 1 study for its GABA-aminotransferase inhibitor, OV329, in Q4 2022 after FDA IND clearance. They are collaborating with Gensaic for genetic epilepsy programs while optimizing other compounds in their pipeline. The company remains committed to maintaining a sufficient cash runway and advancing its epilepsy-related projects.
Ovid Therapeutics Inc. (NASDAQ: OVID) will present at the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022, at 9:00 a.m. ET in New York. A live webcast will be available on the company's website, with an archived replay accessible post-event. Ovid is focused on developing medicines for brain disorders and epilepsies, including their candidates OV329 and OV350, aimed at treatment-resistant seizures. The company holds a financial interest in soticlestat, a drug in Phase 3 trials for specific epilepsy syndromes.
Ovid Therapeutics Inc. (NASDAQ: OVID) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference in New York on September 12, 2022, at 12:00 p.m. ET. The company's focus is on developing medicines for epilepsy and brain disorders. A live webcast of the presentation will be available on their website, along with an archived replay. Ovid is advancing treatments like OV329 and OV350, targeting epilepsy, and is involved in the Phase 3 trials of soticlestat, a collaboration with Takeda.
Ovid Therapeutics (NASDAQ: OVID) reported its Q2 2022 financial results, ending with cash and marketable securities of $152.4 million, supporting ongoing epilepsy pipeline development into 2025. The company plans to file an Investigational New Drug application for OV329, a GABA-aminotransferase inhibitor, in the second half of 2022. Preclinical data from six animal models indicate a strong anti-seizure potential for OV329. Net loss for the quarter was approximately $14.6 million, slightly improved from $15.8 million in Q2 2021.
Ovid Therapeutics (NASDAQ: OVID) presented promising preclinical data for OV329, a next-generation GABA-aminotransferase inhibitor targeting rare and treatment-resistant epilepsies. OV329 showed strong anti-seizure activity across various models, significantly reducing seizures by over 70% in a focal seizure model. Notably, it demonstrated an improved ocular safety profile compared to existing treatments. Ovid plans to submit an Investigational New Drug application in the second half of 2022, aiming to initiate clinical studies later this year.